Drug Profile
Fosgonimeton - Athira Pharma
Alternative Names: ATH-1017; NDX-1017Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator M3 Biotechnology
- Developer Athira Pharma
- Class Amides; Amino acids; Antidementias; Antiparkinsonians; Benzyl compounds; Phosphates; Small molecules
- Mechanism of Action Hepatocyte growth factor stimulants; Proto-oncogene protein c-met stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Alzheimer's disease
- Phase II Dementia; Parkinson's disease
Most Recent Events
- 08 Mar 2024 Efficacy data from a phase-II clinical trials in Dementia and Parkinson's disease released by Athira Pharma
- 08 Mar 2024 Pharmacodynamics data from a preclinical trial in Parkinson's disease released by Athira Pharma
- 08 Mar 2024 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by Athira Pharma